Evolus, Inc.
EOLSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Evolus, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. The company carries a $586.5M market cap, placing it firmly in the small-cap category. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Market Cap
$586.5M
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
32.17
EPS (TTM)
$-0.53
EPS (Fwd)
$0.28
ROE
—
ROA
-5.7%
Cash
$45.2M
Total Debt
$164.8M
Free CF
-$1.8M
52W Change
26.5%
Annual Financials
Cash vs Debt
Where EOLS stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, EOLS finished 55.73% above its 150-day moving average ($5.76) and 50.00% above its 200-day moving average ($5.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EOLS overbought or oversold?
At the August 26, 2026 close, EOLS's RSI(14) was 79.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $45.2M in cash, though total debt stands at $164.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$1.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $148.6M (2022) to $297.2M (2025), reflecting a 100% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EOLS.